In the Healthcare Industry, we often view the access challenge as incredibly difficult in order for the UK to reimburse and recommend new, innovative therapies. But how do we really perform in the most innovative Cell and Gene therapies? How does UK Pharma feel about the challenge? Does the current pace of change correlate with…